Galectin Therapeutics (GALT) Cash from Operations (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Cash from Operations of 3866000.0 for Q1 2026, up 49.72% year-over-year from 2582146.8 in Q1 2025, and up 36.62% quarter-over-quarter from 6100000.0 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Cash from Operations (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 3866000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 49.72% year-over-year to 3866000.0; the TTM figure through Mar 2026 stood at 20077000.0 (up 46.25% YoY), while the FY2025 annual figure was 23900000.0, up 42.78% from the prior year.
- Cash from Operations for Q1 2026 stood at 3866000.0, up from 6100000.0 in the prior quarter.
- The five-year high for Cash from Operations was 3500000.0 in Q3 2025, with the low at 12791000.0 in Q4 2024.
- The 5-year median for Cash from Operations is 7689000.0 (2025), against an average of 7858176.47.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations plunged 170.02% in 2024, then soared 59.19% in 2025.
- Galectin Therapeutics' Cash from Operations stood at 7239000.0 in 2022, then jumped by 34.56% to 4737000.0 in 2023, then slumped by 170.02% to 12791000.0 in 2024, then jumped by 52.31% to 6100000.0 in 2025, then surged by 36.62% to 3866000.0 in 2026.
- Business Quant data shows GALT's Cash from Operations at 3866000.0 in Q1 2026, 6100000.0 in Q4 2025, and 3500000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | -2.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.41 Mn |
| Mar 31, 2026 | -3.90 Mn |
| Dec 31, 2025 | -6.07 Mn |
| Sep 30, 2025 | -3.53 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -7.70 Mn |
| Dec 31, 2024 | -12.80 Mn |
| Sep 30, 2024 | -8.56 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Dec 31, 2023 | -4.74 Mn |
| Sep 30, 2023 | -7.64 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Mar 31, 2023 | -10.79 Mn |
| Dec 31, 2022 | -7.24 Mn |
| Sep 30, 2022 | -8.35 Mn |
| Jun 30, 2022 | -7.43 Mn |
| Mar 31, 2022 | -8.04 Mn |
| Dec 31, 2021 | -6.95 Mn |
| Sep 30, 2021 | -5.00 Mn |